Mission statement · Company scope
“Our mission is to maximize the value of ganaxolone as a best-in-class therapy for rare seizure and neurological disorders through development of multiple formulations for oral and IV administration.”
In use2024 – now1 sighting
First seenMar 2024Added
Last seenMar 2024Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Market leadership (primary)
- Leads with
- Rank
- Best for
- Climate & health
- Formula
- The [rank] [category] for [who]
- Tone
- Plain
- Length
- 29 words · reading grade 18.6
- Review status
- auto accepted · classifier rules-v0
- Quality score
- 0.76
- Record
- st_a8d1ea2aaec9949e
- Classification confidence
- 0.85
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2024-03-05 · sec_sentence · 10-K · accession 0001558370-24-002479
View filing ↗0 to compareCompare